Dr. Bredesen Shares Breakthrough Alzheimer’s Trial Results in Interview With Jesse Chapus

In a recent interview on The Jesse Chappus Show, Dale Bredesen, M.D., shared new insights from a randomized controlled trial evaluating a precision medicine approach to cognitive decline. The study, now available as a preprint with peer review underway, found statistically significant improvements in memory and cognition among participants receiving the multi-factor intervention, whereas those receiving standard care showed declines.

Bredesen emphasized that Alzheimer’s disease is increasingly understood as a multi-factor condition driven by contributors such as metabolic dysfunction, inflammation, toxins, infections, and lifestyle factors. The trial results support targeting these root causes simultaneously, rather than relying on single-drug therapies.

He also highlighted advances in early detection, including blood-based biomarkers such as p-tau217, which can identify risk decades before symptoms appear. This enables earlier intervention, an approach he argues can make cognitive decline largely preventable.

Watch Here: